))
Columvi, Linzess, Recell, Bylvay, Eroxon
Manage episode 407556919 series 3561458
Treść dostarczona przez Emma Nichols, PhD and Emma Hitt Nichols. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Emma Nichols, PhD and Emma Hitt Nichols lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.
Get our free download! Implementing AMA Style – 8 Things to Get Right
In this episode, we discuss the latest FDA approvals from June 12 – June 16, 2023. Here are the key highlights:
· The FDA has granted accelerated approval to Roche's Columvi® (glofitamab) for the treatment of DLBCL and large B-cell lymphoma.
· Linzess® (linaclotide) capsules have been approved by the FDA to treat functional constipation in pediatric patients aged 6 to 17 years.
· The FDA has granted premarket approval to the RECELL® autologous cell harvesting device for the treatment of vitiligo, a skin condition characterized by depigmentation.
· Bylvay® (odevixibat) has received FDA approval for the treatment of cholestatic pruritus in patients with Alagille syndrome.
· The FDA has approved Eroxon®, a topical gel, as an over-the-counter treatment for erectile dysfunction.
If you need medical writing assistance please visit Nascent Medical. Nascent Medical specialize in high-quality medical writing services and they are available on call to meet your deadlines. Nascentmc.com
Intro and outro music
47 odcinków
Udostępnij
